TScan Therapeutics, Inc. (TCRX)
NASDAQ: TCRX · Real-Time Price · USD
1.920
-0.210 (-9.86%)
At close: Oct 29, 2025, 4:00 PM EDT
2.000
+0.080 (4.17%)
After-hours: Oct 29, 2025, 7:41 PM EDT
TScan Therapeutics Revenue
TScan Therapeutics had revenue of $3.08M in the quarter ending June 30, 2025, with 473.88% growth. This brings the company's revenue in the last twelve months to $6.96M, down -42.94% year-over-year. In the year 2024, TScan Therapeutics had annual revenue of $2.82M, down -86.62%.
Revenue (ttm)
$6.96M
Revenue Growth
-42.94%
P/S Ratio
15.65
Revenue / Employee
$35,697
Employees
195
Market Cap
108.96M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 2.82M | -18.23M | -86.62% |
| Dec 31, 2023 | 21.05M | 7.51M | 55.52% |
| Dec 31, 2022 | 13.54M | 3.39M | 33.47% |
| Dec 31, 2021 | 10.14M | 9.06M | 834.65% |
| Dec 31, 2020 | 1.09M | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
TCRX News
- 6 weeks ago - TScan Therapeutics Announces Upcoming Oral and Poster Presentations at the American College of Rheumatology Convergence 2025 - GlobeNewsWire
- 2 months ago - TScan Therapeutics to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 2 months ago - TScan Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewsWire
- 5 months ago - TScan Therapeutics Announces Upcoming Presentation at the Jefferies Global Healthcare Conference - GlobeNewsWire
- 6 months ago - TScan Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewsWire
- 6 months ago - TScan Therapeutics Announces Upcoming Presentation at the American Society of Gene and Cell Therapy 28th Annual Meeting - GlobeNewsWire
- 7 months ago - TScan Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference - GlobeNewsWire
- 7 months ago - TScan Therapeutics Appoints Commercial Leader Stephen Camiolo as Senior Vice President, Market Access - GlobeNewsWire